DK1322336T3 - Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinder - Google Patents
Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinderInfo
- Publication number
- DK1322336T3 DK1322336T3 DK01964525.8T DK01964525T DK1322336T3 DK 1322336 T3 DK1322336 T3 DK 1322336T3 DK 01964525 T DK01964525 T DK 01964525T DK 1322336 T3 DK1322336 T3 DK 1322336T3
- Authority
- DK
- Denmark
- Prior art keywords
- women
- procedure
- increasing testosterone
- steroid concentrations
- related steroid
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 2
- 150000003431 steroids Chemical class 0.000 title 1
- 229960003604 testosterone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/651,777 US6503894B1 (en) | 2000-08-30 | 2000-08-30 | Pharmaceutical composition and method for treating hypogonadism |
| US70375300A | 2000-11-01 | 2000-11-01 | |
| US29239801P | 2001-05-21 | 2001-05-21 | |
| PCT/US2001/027199 WO2002017967A1 (en) | 2000-08-30 | 2001-08-29 | Method of increasing testosterone and related steroid concentrations in women |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1322336T3 true DK1322336T3 (da) | 2013-07-15 |
Family
ID=27404127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01964525.8T DK1322336T3 (da) | 2000-08-30 | 2001-08-29 | Fremgangsmåde til forøgelse af testosteron og beslægtede steroidkoncentrationer hos kvinder |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1322336B1 (enExample) |
| JP (1) | JP2004507511A (enExample) |
| KR (1) | KR20030048021A (enExample) |
| CN (1) | CN100349572C (enExample) |
| AU (2) | AU8536701A (enExample) |
| BR (1) | BR0113649A (enExample) |
| CA (1) | CA2419573C (enExample) |
| DK (1) | DK1322336T3 (enExample) |
| ES (1) | ES2423899T3 (enExample) |
| IL (2) | IL154693A0 (enExample) |
| MX (1) | MXPA03001859A (enExample) |
| NO (1) | NO334991B1 (enExample) |
| NZ (1) | NZ536633A (enExample) |
| PL (1) | PL360992A1 (enExample) |
| PT (1) | PT1322336E (enExample) |
| WO (1) | WO2002017967A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| CA2418135C (en) | 2000-08-03 | 2011-09-20 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| MXPA04008988A (es) * | 2002-03-15 | 2006-05-25 | Unimed Pharmaceuticals Inc | Composicion androgena farmaceutica y metodo para el tratamiento de la depresion. |
| BR0308584A (pt) * | 2002-03-15 | 2005-02-22 | Unimed Pharmaceuticals Inc | Composição farmacêutica androgênica e método para tratamento de depressão |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| WO2004000263A1 (en) | 2002-06-25 | 2003-12-31 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
| AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
| AU2003240299B2 (en) * | 2002-06-25 | 2008-01-31 | Acrux Dds Pty. Ltd. | Metastable pharmaceutical compositions |
| US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| CA2538856C (en) | 2003-10-10 | 2010-06-29 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| US7425340B2 (en) | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
| AU2006235453A1 (en) * | 2005-04-12 | 2006-10-19 | Laboratories Besins International | Method of treating or preventing bone deterioration or osteoporosis |
| KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
| WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| KR20130114229A (ko) | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | 경피 약물 전달 방법 및 조성물 |
| EP1896038B1 (en) * | 2005-06-03 | 2016-11-09 | Acrux DDS Pty Ltd | Method and composition for testosterone transdermal delivery |
| RS52671B (sr) | 2005-10-12 | 2013-06-28 | Unimed Pharmaceuticals Llc | Poboljšani gel testosterona i postupak korišćenja |
| EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
| PH12012500882A1 (en) | 2009-12-23 | 2013-01-07 | Colgate Palmolive Co | Oral care system, kit and method |
| BR112012015730A2 (pt) | 2009-12-23 | 2021-07-06 | Colgate Palmolive Co | sistema de tratamento bucal. |
| KR101528395B1 (ko) | 2009-12-23 | 2015-06-11 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템 |
| KR101513342B1 (ko) | 2009-12-23 | 2015-04-17 | 콜게이트-파아므올리브캄파니 | 구강 관리 시스템 |
| US9642862B2 (en) | 2010-11-18 | 2017-05-09 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
| US12186326B2 (en) | 2018-07-05 | 2025-01-07 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
| AU2021216630A1 (en) | 2020-02-05 | 2022-09-22 | Neurocrine UK Limited | Testosterone containing pharmaceutical composition |
| CN115754070B (zh) * | 2022-11-24 | 2025-11-25 | 深圳市第二人民医院(深圳市转化医学研究院) | 同时测定血液中总睾酮和游离睾酮含量的方法及试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
| US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| PT1382340E (pt) * | 1993-01-19 | 2006-07-31 | Endorech Inc | Utilizacoes terapeuticas de desidroepiandrosterona para tratar libido diminuida e osteoporose |
| US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
| DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| KR20000070757A (ko) * | 1997-02-07 | 2000-11-25 | 에버트 챨스 디 | 테스토스테론 결핍증이 나타나는 여성에게 테스토스테론을 보충하는 방법 및 이에 이용되는 조성물 |
| US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
| CA2309688C (en) * | 1997-11-10 | 2007-04-24 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
-
2001
- 2001-08-29 KR KR10-2003-7003111A patent/KR20030048021A/ko not_active Ceased
- 2001-08-29 AU AU8536701A patent/AU8536701A/xx active Pending
- 2001-08-29 CA CA002419573A patent/CA2419573C/en not_active Expired - Lifetime
- 2001-08-29 IL IL15469301A patent/IL154693A0/xx unknown
- 2001-08-29 PL PL01360992A patent/PL360992A1/xx not_active Application Discontinuation
- 2001-08-29 WO PCT/US2001/027199 patent/WO2002017967A1/en not_active Ceased
- 2001-08-29 CN CNB018164331A patent/CN100349572C/zh not_active Expired - Lifetime
- 2001-08-29 BR BR0113649-6A patent/BR0113649A/pt not_active Application Discontinuation
- 2001-08-29 ES ES01964525T patent/ES2423899T3/es not_active Expired - Lifetime
- 2001-08-29 MX MXPA03001859A patent/MXPA03001859A/es active IP Right Grant
- 2001-08-29 JP JP2002522940A patent/JP2004507511A/ja active Pending
- 2001-08-29 AU AU2001285367A patent/AU2001285367B2/en not_active Expired
- 2001-08-29 NZ NZ536633A patent/NZ536633A/xx not_active IP Right Cessation
- 2001-08-29 DK DK01964525.8T patent/DK1322336T3/da active
- 2001-08-29 PT PT1964525T patent/PT1322336E/pt unknown
- 2001-08-29 EP EP01964525.8A patent/EP1322336B1/en not_active Expired - Lifetime
-
2003
- 2003-02-28 IL IL154693A patent/IL154693A/en active IP Right Grant
- 2003-02-28 NO NO20030954A patent/NO334991B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20030954D0 (no) | 2003-02-28 |
| IL154693A (en) | 2010-04-15 |
| HK1115537A1 (en) | 2008-12-05 |
| NO334991B1 (no) | 2014-08-18 |
| WO2002017967A1 (en) | 2002-03-07 |
| CN100349572C (zh) | 2007-11-21 |
| IL154693A0 (en) | 2003-09-17 |
| CA2419573A1 (en) | 2002-03-07 |
| EP1322336B1 (en) | 2013-07-03 |
| BR0113649A (pt) | 2004-07-20 |
| MXPA03001859A (es) | 2004-05-21 |
| HK1061804A1 (zh) | 2004-10-08 |
| ES2423899T3 (es) | 2013-09-25 |
| JP2004507511A (ja) | 2004-03-11 |
| EP1322336A1 (en) | 2003-07-02 |
| CN1466467A (zh) | 2004-01-07 |
| NZ536633A (en) | 2006-03-31 |
| CA2419573C (en) | 2007-04-03 |
| KR20030048021A (ko) | 2003-06-18 |
| PT1322336E (pt) | 2013-08-05 |
| NO20030954L (no) | 2003-04-28 |
| AU2001285367B2 (en) | 2006-05-18 |
| AU8536701A (en) | 2002-03-13 |
| PL360992A1 (en) | 2004-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20030954D0 (no) | Fremgangsmåte for å öke testosteron og beslektede konsentrasjoner av steroid hos kvinner | |
| NO20012911L (no) | Fremvisningsanordning og fremgangsmåte for drift av samme | |
| CY2017020I2 (el) | Στεροειδη ως αγωνιστες για τους υποδοχεις fxr | |
| DK1323222T3 (da) | Önet og fremgangsmåde til drift af et önet | |
| NO20025587L (no) | Inhibitorer for 11-beta-hydroxy steroid dehydrogenase type 1 | |
| NO2008006I2 (no) | Fluticasone furoate | |
| DE60133164D1 (de) | Kartendarstellungsverfahren | |
| EE200200519A (et) | Erektsiooni soodustav vahend | |
| FI20000572L (fi) | Implantaattien asettamiseen tarkoitettu laite | |
| DE60034345D1 (de) | Abschaltprotokoll für integrierte Schaltungen | |
| DK1265482T3 (da) | Vandige formulationer og fremgangsmåde til fremstilling af samme | |
| EP1385868A4 (en) | STEROID DERIVATIVE | |
| FI20002875L (fi) | Menetelmä linkkiadaptaation suorittamiseksi | |
| NO20031737L (no) | Östrogenreseptormodulatorer | |
| DK1286317T3 (da) | Fremgangsmåde til at kreditere en konto | |
| DK1139187T3 (da) | Fremgangsmåde og indretning til vækning | |
| DK1589976T3 (da) | Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose | |
| NO20033321D0 (no) | Androgeniske 7-substituerte 11-halogensteroider | |
| DK1517914T3 (da) | 9-alpha-substituerede estratriener som selektivt virksomme östrogener | |
| DK1341758T3 (da) | Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme | |
| DK1230227T3 (da) | Benzoxa- og benzthiazolylsulfamater og anvendelse deraf som steroid-sulfataseinhibitorer | |
| AU2001240071A1 (en) | System and method providing delays for cdma nulling | |
| DK1287721T3 (da) | I öret bærbart höreapparat og fremgangsmåde til dettes fremstilling | |
| NO20030606D0 (no) | Modifisert gj¶r og anvendelser derav, n¶rmere bestemt for fremstilling avsteroidderivater | |
| DK1312008T3 (da) | Apparat og kits til at fastgöre og desinficere implanterede katetre |